Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.
Mangen
Marie-Josee J
MJ
University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3508 GA Utrecht, The Netherlands. m.j.j.mangen@uncutrecht.nl
van Duynhoven
Yvonne T H P
YT
Vennema
Harry
H
van Pelt
Wilfrid
W
Havelaar
Arie H
AH
de Melker
Hester E
HE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D012400:Rotavirus Infections / Q000191:economics* / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000191:economics* / Q000276:immunology*; D014611:Vaccination / Q000191:economics*; D014613:Vaccines, Attenuated / Q000191:economics / Q000276:immunology; D055815:Young Adult
C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated